208 related articles for article (PubMed ID: 34710984)
1. Ketoconazole for the Treatment of Docetaxel-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Review.
Tresnanda RI; Pramod SV; Safriadi F
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3101-3107. PubMed ID: 34710984
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients.
Lo EN; Beckett LA; Pan CX; Robles D; Suga JM; Sands JM; Lara PN
Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):144-8. PubMed ID: 25667107
[TBL] [Abstract][Full Text] [Related]
4. The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
Teply BA; Luber B; Denmeade SR; Antonarakis ES
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):72-8. PubMed ID: 26857146
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer.
Gil-Bazo I; Arévalo E; Castillo A; Zudaire ME; Carranza OE; Fusco JP; Castañón E; Collado-Gómez V; López I; Gil-Aldea I
Clin Genitourin Cancer; 2013 Jun; 11(2):78-84. PubMed ID: 23260990
[TBL] [Abstract][Full Text] [Related]
6. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
Aggarwal R; Halabi S; Kelly WK; George D; Mahoney JF; Millard F; Stadler WM; Morris MJ; Kantoff P; Monk JP; Carducci M; Small EJ;
Cancer; 2013 Oct; 119(20):3636-43. PubMed ID: 23913744
[TBL] [Abstract][Full Text] [Related]
7. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M
BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821
[TBL] [Abstract][Full Text] [Related]
8. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
[TBL] [Abstract][Full Text] [Related]
9. Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors.
Fan L; Dong B; Chi C; Wang Y; Gong Y; Sha J; Pan J; Shangguan X; Huang Y; Zhou L; Xue W
BMC Urol; 2018 Dec; 18(1):110. PubMed ID: 30509237
[TBL] [Abstract][Full Text] [Related]
10. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ
Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
[TBL] [Abstract][Full Text] [Related]
11. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
[TBL] [Abstract][Full Text] [Related]
12. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
[TBL] [Abstract][Full Text] [Related]
13. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
George DJ; Halabi S; Healy P; Barak I; Winters C; Anand M; Wilder R; Klein M; Martinez E; Nixon AB; Harrison MR; Szmulewitz R; Armstrong AJ
Prostate; 2019 Nov; 79(15):1752-1761. PubMed ID: 31497882
[TBL] [Abstract][Full Text] [Related]
14. Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM
Oncologist; 2019 Sep; 24(9):1188-1194. PubMed ID: 30952818
[TBL] [Abstract][Full Text] [Related]
15. Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide.
Miyake H; Hara T; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
Urol Oncol; 2017 Jun; 35(6):432-437. PubMed ID: 28188090
[TBL] [Abstract][Full Text] [Related]
16. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ
Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611
[TBL] [Abstract][Full Text] [Related]
18. Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel.
Peer A; Gottfried M; Sinibaldi V; Carducci MA; Eisenberger MA; Sella A; Leibowitz-Amit R; Berger R; Keizman D
Prostate; 2014 Apr; 74(4):433-40. PubMed ID: 24338986
[TBL] [Abstract][Full Text] [Related]
19. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I
Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
